---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-23-019198"
form_type: "8-K"
ticker: "SABS"
cik: "0001833214"
company_name: "SAB Biotherapeutics, Inc."
filed_at: "2023-07-03T23:59:59+00:00"
generated_at: "2026-06-13T13:25:52.870909+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.2
calibrated_materiality_score: 0.15
confidence: "high"
source: SEC EDGAR
---

# SAB Biotherapeutics shareholders elect Spragens and Link as Class II directors, ratify auditor

## Summary
- Shareholders elected Jeffrey G. Spragens and David Link as Class II directors for three-year terms expiring at 2026 annual meeting.
- Appointment of Mayer Hoffman McCann P.C. as independent auditor for FY 2023 ratified with 37.25M votes for, 33K against.
- Over 37.5M shares voted, representing 74.45% of outstanding shares, constituting a quorum.

## SEC filing metadata
- accession: 0001437749-23-019198
- form_type: 8-K
- ticker: SABS
- cik: 0001833214
- company_name: SAB Biotherapeutics, Inc.
- filed_at: 2023-07-03T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.2
- calibrated_materiality_score: 0.15
- confidence: high
- sec_items: 5.07
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1833214/000143774923019198/0001437749-23-019198-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1833214/000143774923019198/sabs20230629c_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-23-019198
- JSON: https://secwatch.observer/filing/0001437749-23-019198.json
- Plain text: https://secwatch.observer/filing/0001437749-23-019198.txt

## Key facts
- Shareholder Votes
  SAB Biotherapeutics, Inc. shareholders approved Ratify the appointment of Mayer Hoffman McCann P.C. as independent registered public accounting firm at the 2023-06-29 meeting.
  - Proposal: auditor ratification
  - Outcome: passed
  - Meeting: 2023-06-29
  source text: Proposal 2: Ratify the appointment of Mayer Hoffman McCann P.C. as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2023 Votes For Votes Against Abstentions 37,253,986 33,433 235,486
  evidence_url: https://www.sec.gov/Archives/edgar/data/1833214/000143774923019198/0001437749-23-019198-index.htm
- Shareholder Votes
  SAB Biotherapeutics, Inc. shareholders approved Election of two Class II directors at the 2023-06-29 meeting.
  - Proposal: director election
  - Outcome: passed
  - Meeting: 2023-06-29
  source text: Proposal 1: Election of two Class II directors Director Votes For Withheld Broker Non-Votes Jeffrey G. Spragens 30,399,580 403,139 6,720,186 David Link 30,402,160 400,559 6,720,186
  evidence_url: https://www.sec.gov/Archives/edgar/data/1833214/000143774923019198/0001437749-23-019198-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.